|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0010802,
umls-concept:C0023473,
umls-concept:C0030705,
umls-concept:C0205263,
umls-concept:C0231199,
umls-concept:C0457343,
umls-concept:C0683598,
umls-concept:C0871261,
umls-concept:C0935989,
umls-concept:C1455147,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2008-6-11
|
|
pubmed:abstractText |
Dasatinib, a potent inhibitor of BCR-ABL in vitro, is effective for patients with chronic myelogenous leukemia (CML) resistant or intolerant to imatinib. To provide a more definitive assessment of dasatinib in chronic-phase (CP)-CML, we report extended follow-up of a phase II trial, presenting data for the entire patient cohort (N=387). Dasatinib (70 mg) twice daily was administered to patients with imatinib-resistant or -intolerant CP-CML. With median follow-up of 15.2 months (treatment duration, <1-18.4 months), a complete hematologic response was attained or maintained in 91% of patients. A major cytogenetic response (MCyR) was attained or maintained by 59% (52% imatinib resistant and 80% imatinib intolerant); this was complete in 49% of patients (40% imatinib resistant and 75% imatinib intolerant). Of 230 patients achieving an MCyR, 7 experienced disease progression. Fifteen-month progression-free survival was 90% while overall survival was 96%. Grade 3/4 thrombocytopenia and neutropenia were reported in 48 and 49% of patients, respectively. Non-hematologic toxicity (any grade) consisted primarily of diarrhea (37%), headache (32%), fatigue (31%), dyspnea (30%) and pleural effusion (27%). Pleural effusions were classified as grade 3 in 6% of reported events, with no incidence of grade 4. Dasatinib is associated with high response rates in patients with imatinib-resistant or -intolerant CP-CML.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1476-5551
|
|
pubmed:author |
pubmed-author:ApperleyJ FJF,
pubmed-author:BaccaraniMM,
pubmed-author:CervantesFF,
pubmed-author:CormSS,
pubmed-author:CountouriotisA MAM,
pubmed-author:DeiningerMM,
pubmed-author:DombretHH,
pubmed-author:EzzeddineRR,
pubmed-author:GoldbergS LSL,
pubmed-author:HochhausAA,
pubmed-author:HughesTT,
pubmed-author:KantarjianH MHM,
pubmed-author:LarsonR ARA,
pubmed-author:LiptonJ HJH,
pubmed-author:MüllerM CMC,
pubmed-author:NiederwieserDD,
pubmed-author:RoyLL,
pubmed-author:ShahN PNP,
pubmed-author:SilverR TRT,
pubmed-author:StoneR MRM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1200-6
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:18401416-Adult,
pubmed-meshheading:18401416-Aged,
pubmed-meshheading:18401416-Disease-Free Survival,
pubmed-meshheading:18401416-Drug Resistance, Neoplasm,
pubmed-meshheading:18401416-Female,
pubmed-meshheading:18401416-Follow-Up Studies,
pubmed-meshheading:18401416-Fusion Proteins, bcr-abl,
pubmed-meshheading:18401416-Humans,
pubmed-meshheading:18401416-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:18401416-Leukemia, Myeloid, Chronic-Phase,
pubmed-meshheading:18401416-Male,
pubmed-meshheading:18401416-Maximum Tolerated Dose,
pubmed-meshheading:18401416-Middle Aged,
pubmed-meshheading:18401416-Mutation,
pubmed-meshheading:18401416-Piperazines,
pubmed-meshheading:18401416-Protein Kinase Inhibitors,
pubmed-meshheading:18401416-Protein-Tyrosine Kinases,
pubmed-meshheading:18401416-Pyrimidines,
pubmed-meshheading:18401416-Survival Rate,
pubmed-meshheading:18401416-Thiazoles,
pubmed-meshheading:18401416-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
|
|
pubmed:affiliation |
III Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany. hochhaus@uni-hd.de
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
